Latest International Markets News

Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.

BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective June 2026, aiming to accelerate its commercial rollout and international market entry of early cancer detection tests.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

Block, Inc. reported a robust Q1 2026 with AI-powered productivity gains, strong Cash App and Square growth, and a $5 billion share buyback boost. Despite a GAAP net loss due to restructuring and legal costs, the fintech giant raised its full-year outlook, signaling confidence in its AI-led transformation.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Comvita has secured the minimum NZ$25 million capital raise required to activate its refinancing plan, driven by strong shareholder participation and Fraser and Neave’s near 20% stake. The Rights Offer closes today, setting the stage for debt repayment and financial restructuring.

Acusensus Limited maintains its FY26 revenue and EBITDA guidance while advancing multiple enforcement programs across the US, UK, New Zealand, and Australia, underpinned by new product developments and international growth.

Regal Partners showcased its diversified $21 billion funds under management and ongoing growth momentum at the Macquarie Australia Conference, emphasising strong inflows, product innovation, and offshore expansion.

Sigma Healthcare reports robust growth in Chemist Warehouse sales across Australia and internationally, announces a joint venture to enter the UK market, and secures a major distribution centre lease in New Zealand to support its expanding network.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

OpenLearning accelerated its SaaS annual recurring revenue by 35% year-on-year to $3.192 million in Q1 FY26, propelled by larger multi-year LMS contracts and ongoing AI platform enhancements.